Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,634 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Cognitive Therapy for Recurrent Depression

NCT00118404
View directory record Official record
Conditions
Depression
Interventions
Continuation phase cognitive therapy, Continuation phase fluoxetine, Continuation phase pill placebo, Acute phase cognitive therapy
Behavioral · Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 27, 2026, 8:26 PM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

NCT05355753
View directory record Official record
Conditions
Synovial Sarcoma, Soft Tissue Sarcoma
Interventions
CFT8634
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

NCT00700167
View directory record Official record
Conditions
Melanoma
Interventions
dendritic cell vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

NCT01899105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
lumacaftor, ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 3 Interventional

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

NCT04175613
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 27, 2026, 8:26 PM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

NCT05075824
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 27, 2026, 8:26 PM EDT
Terminated Not applicable Interventional

Laser Dosage in MicroPulse TransScleral CycloPhotocoagulation

NCT04709679
View directory record Official record
Conditions
Glaucoma
Interventions
MicroPulse TransScleral CycloPhotoCoagulation
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

NCT04686279
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir Douche
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 24 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 27, 2026, 8:26 PM EDT
Not yet recruiting Not applicable Interventional

Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy

NCT07424079
View directory record Official record
Conditions
Cerebral Palsy (CP)
Interventions
Pathways and Resources for Engagement and Participation, Attention Control Condition
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
13 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 27, 2026, 8:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

NCT04855773
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
PrEPmate, Dot Diary
Other · Device
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
15 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Fluconazole, Rifampin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 8:26 PM EDT
Terminated Early Phase 1 Interventional

Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor

NCT02069080
View directory record Official record
Conditions
Cancer
Interventions
64-Cu-plerixafor
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 27, 2026, 8:26 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

NCT03059303
View directory record Official record
Conditions
Healthy
Interventions
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

NCT00698841
View directory record Official record
Conditions
Advanced Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Casa Grande, Arizona • Corona, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

NCT01041859
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tapentadol extended release (ER), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
60
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Precision High-Intensity Training Through Epigenetics (PHITE)

NCT03380923
View directory record Official record
Conditions
Healthy
Interventions
Moderate Intensity, High Intensity
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 27 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 27, 2026, 8:26 PM EDT
Recruiting Not applicable Interventional

CHAMP Lung Cancer Screening Program

NCT07572773
View directory record Official record
Conditions
Lung Cancer, Early Lung Cancer Detection
Interventions
DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan
Diagnostic Test
Lead sponsor
Jill Kolesar
Other
Eligibility
50 Years to 77 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Iowa City, Iowa • Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 27, 2026, 8:26 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures

NCT01564407
View directory record Official record
Conditions
Restrictive Scar Contracture, Restrictive Hypertrophic Scar, Burn Scar Contractures, Burn Scar
Interventions
ICX-RHY-013
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 27, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin and GSK376501

NCT00605449
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 27, 2026, 8:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

NCT06439992
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 27, 2026, 8:26 PM EDT